The Centre’s decision to restrict over-the-counter sales of cough syrups is a positive step, but systemic weaknesses in India’s drug regulatory framework continue to undermine effective oversight
The Union Health Ministry has eased pharmaceutical regulations, allowing companies to start drug development and low-risk clinical studies via online intimation to CDSCO, cutting approval timelines, reducing regulatory burden, and boosting research and innovation in the Indian pharma sector
